指南与共识膀胱癌与上尿路尿路上皮癌

国际共识声明:膀胱肿瘤整块切除术(ERBT)的标准化与研究方向

An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting.
指南 / 共识 · Eur Urol · 2020-05-08

该共识采用改良Delphi法,基于两项系统评价、两轮200名医护人员参与的调查及16人共识会议制定。系统评价纳入10项RCT,显示ERBT较TURBT缩短冲洗时间(均差-7.24小时,95%CI -9.29至-5.20)并降低膀胱穿孔率(RR 0.30,95%CI 0.11-0.83),复发无显著差异。共形成103条陈述,99条达成共识,为ERBT临床实践提供 interim 指导。

要点

  • ERBT应始终考虑用于非肌层浸润性膀胱癌的治疗。
  • 即使肿瘤>3 cm,ERBT仍可行;肿瘤数目和位置非主要限制。
  • 计划环周切缘应距可见肿瘤至少5 mm,术后不常规行肿瘤边缘或基底活检。

核心结论

  • ERBT可作为TURBT的肿瘤学非劣效替代方案,并发症更少、标本质量更好,但缺乏稳健RCT数据。
  • 共识提供了ERBT标准化的 interim 指导,并指出未来研究方向。

研究设计与样本

  • 采用改良Delphi法:先进行两项系统评价(有效性评价和不确定性评价),再邀请200名有ERBT经验的医护人员完成两轮调查,最后召开16人共识会议。
  • 有效性评价对RCT数据进行Meta分析,共识定义:≥70%评分7-9且≤15%评分1-3为同意;或≥70%评分1-3且≤15%评分7-9为不同意。

主要发现

  • 系统评价共纳入10项RCT。
  • ERBT较TURBT冲洗时间更短(均差-7.24小时,95%CI -9.29至-5.20,I²=85%,p<0.001),证据确定性中等。
  • ERBT较TURBT膀胱穿孔率更低(风险比0.30,95%CI 0.11-0.83,I²=1%,p=0.02),证据确定性中等。
  • 0-12、13-24、25-36个月复发率无显著差异(证据确定性极低)。
  • 共形成103条陈述,99条达成共识。

关键数值与推荐

  • ERBT应始终考虑用于非肌层浸润性膀胱癌的治疗。
  • 即使膀胱肿瘤大于3 cm,ERBT也应被视为可行。
  • 膀胱肿瘤的数目和位置不是实施ERBT的主要限制。
  • 计划环周切缘应距任何可见膀胱肿瘤至少5 mm。
  • ERBT后不应常规对肿瘤边缘或肿瘤基底部进行额外活检。

临床怎么用

  • 临床医生可将共识陈述用于标准化ERBT操作,包括适应证选择、切缘规划、标本评估及术后辅助治疗。
  • 研究者可参考共识中识别的未来ERBT研究重要结局设计临床试验。

局限性

  • 共识陈述简短、简明且二元化,可能无法充分处理复杂的 uncertainty 领域。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There has been increasing interest in en bloc resection of bladder tumour (ERBT) as an oncologically noninferior alternative to transurethral resection of bladder tumour (TURBT) with fewer complications and better histology specimens. However, there is a lack of robust randomised controlled trial (RCT) data for making recommendations. OBJECTIVE: We aimed to develop a consensus statement to standardise various aspects of ERBT for clinical practice and to guide future research. DESIGN, SETTING, AND PARTICIPANTS: We developed the consensus statement on ERBT using a modified Delphi method. First, two systematic reviews were performed to investigate the clinical effectiveness of ERBT versus TURBT (effectiveness review) and to identify areas of uncertainty in ERBT (uncertainties review). Next, 200 health care professionals (urologists, oncologists, and pathologists) with experience in ERBT were invited to complete a two-round Delphi survey. Finally, a 16-member consensus panel meeting was held to review, discuss, and re-vote on the statements as appropriate. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Meta-analyses were performed for RCT data in the effectiveness review. Consensus statements were developed from the uncertainties review. Consensus was defined as follows: (1) ≥70% scoring a statement 7-9 and ≤15% scoring the statement 1-3 (consensus agree), or (2) ≥70% scoring a statement 1-3 and ≤15% scoring the statement 7-9 (consensus disagree). RESULTS AND LIMITATIONS: A total of 10 RCTs were identified upon systematic review. ERBT had a shorter irrigation time (mean difference -7.24 h, 95% confidence interval [CI] -9.29 to -5.20, I2 = 85%, p < 0.001) and a lower rate of bladder perforation (risk ratio 0.30, 95% CI 0.11-0.83, I2 = 1%, p = 0.02) than TURBT, both with moderate certainty of evidence. There were no significant differences in recurrences at 0-12, 13-24, or 25-36 mo (all very low certainty of evidence). A total of 103 statements were developed, of which 99 reached a consensus. A summary of statements is as follows: ERBT should always be considered for treating non-muscle-invasive bladder cancer; ERBT should be considered feasible even for bladder tumours larger than 3 cm; number and location of bladder tumours are not major limitations in performing ERBT; the planned circumferential margin should be at least 5 mm from any visible bladder tumour; after ERBT, additional biopsy of the tumour edge or tumour base should not be performed routinely; for the ERBT specimen, T1 substage, and circumferential and deep resection margins must be assessed; it is safe to give a single dose of immediate intravesical chemotherapy, perform second-look transurethral resection, and give intravesical bacillus Calmette-Guérin (BCG) therapy after ERBT; and in studies of ERBT, both per-patient and -tumour analysis should be performed for different outcomes as appropriate. Important outcomes for future ERBT studies were also identified. A limitation is that as consensus statements are brief, concise and binary in nature, areas of uncertainty that are complex in nature may not be addressed adequately. CONCLUSIONS: We have provided the most comprehensive review of the evidence base to date using a meta-analysis where appropriate and applying the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology, and mobilised the international urology community to develop a consensus statement on ERBT using transparent and robust methods. The consensus statement will provide interim guidance for health care professionals who practice ERBT and inform researchers regarding ERBT-related studies in the future. PATIENT SUMMARY: En bloc resection of bladder tumour (ERBT) is a surgical technique aiming to resect a bladder tumour in one piece. We included an international panel of experts to agree on the best practice of ERBT, and this will provide guidance to clinicians and researchers in the future.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Teoh JY, MacLennan S, Chan VW, et al. An International Collaborative Consensus Statement on En Bloc Resection of Bladder Tumour Incorporating Two Systematic Reviews, a Two-round Delphi Survey, and a Consensus Meeting. Eur Urol. 2020. PMID: 32389447. doi:10.1016/j.eururo.2020.04.059

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。